Dyslipidemia

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Experts discussed FCS diagnostic scoring tools, diagnostic delays, and new data on olezarsen and plozasiran for lowering triglycerides in a recent clinical forum.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Elif Oral, MD, discusses the clinical implications of the recent data emphasizing metreleptin’s anti-drug antibodies and their llack of impact on efficacy.